Menu
Sign In Pricing Add Podcast
Podcast Image

BackTable Urology

Ep. 156 Comedy, Cancer, and Courage: Navigating a Testis Cancer Diagnosis with Comedian Nimesh Patel

Tue, 12 Mar 2024

Description

Disclaimer: This podcast episode contains occasional profanity. While we strive to maintain a respectful and professional tone in our content, there may be instances where language is used to emphasize points or express strong emotions. Listener discretion is advised. This week on BackTable Urology, Dr. Ruchika Talwar interviews Emmy nominated writer and comedian, Nimesh Patel, about his personal experience with testicular cancer. Sharing about his diagnosis, treatment, and recovery, Nimesh describes how he processed his cancer and used it as a source of comedic material for his 2023 comedy special, “Lucky Lefty”. His story has contributed to testicular cancer awareness by encouraging men to do self-checks and seek medical attention. Nimesh also underlines the importance of swift medical attention, open communication with medical professionals, and finding a healthy outlet for processing the fear and stress that can accompany a cancer diagnosis. Finally, he emphasizes the importance of the patient-physician relationship, as his anxiety about his diagnosis was eased his physician’s calm demeanor and reassurance. --- SHOW NOTES 00:00 - Introduction 02:06 - The Testicular Cancer Diagnosis and Personal Reflections 11:39 - Sharing His Cancer Journey through Comedy 19:56 - Advice for Physicians and Physicians 25:11 - Advice for Men Facing Testicular Cancer 27:36 - The Importance of Not Making Cancer Your Personality --- RESOURCES Nimesh Patel’s “Lucky Lefty” Comedy Special https://www.youtube.com/watch?v=A2Rdh82XGrY Episode 91- When Providers Become Patients: Testicular Cancer and Beyond with Dr. William Flanary aka. Dr. Glaucomflecken https://open.spotify.com/episode/4JSXDRJ8BwzFhBBpCymCU3?si=8c58881f9b274cd0

Audio
Featured in this Episode

No persons identified in this episode.

Transcription
Comments

There are no comments yet.

Please log in to write the first comment.